Form 3 Filing for BridgeBio Oncology Therapeutics, Inc.

This filing details the beneficial ownership of securities for Idan Elmelech, COO & Principal Financial Officer of BridgeBio Oncology Therapeutics, Inc. (BBOT). The filing includes information on directly held Common Stock, specifically 14,838 shares represented by restricted stock units that vest in installments through January 1, 2030. It also outlines various stock options granted to Elmelech, with different exercise prices and expiration dates, all of which are exercisable for Common Stock. These options vest in installments through monthly anniversaries of dates ranging from May 1, 2024, to January 1, 2026. Additionally, the filing includes a Limited Power of Attorney, appointing specific individuals to execute SEC forms on behalf of Elmelech, effective April 20, 2026.